Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer
- 1Department of Surgery, University of Virginia Health System, Charlottesville, VA 22903, USA
- 2Division of Cardiothoracic Surgery, Department of Surgery, University of Virginia Health System, Charlottesville, VA 22903, USA
Abstract
The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety and significant efficacy of biomarker-directed therapies in metastatic disease have fueled interest in applying precision oncology to early-stage, operable NSCLC. Advances in molecular profiling have revealed that a substantial proportion of resected NSCLC harbor actionable driver mutations, enabling the integration of targeted therapies into the perioperative setting. The success of adjuvant epidermal growth factor receptor and anaplastic lymphoma kinase inhibition established a framework for biomarker-driven therapy and highlights the importance of comprehensive molecular testing at diagnosis. In parallel, perioperative immune checkpoint inhibitor-based strategies have expanded treatment options for appropriately selected patients, further emphasizing the importance of molecular profiling. Significant implementation gaps remain, including incomplete molecular testing, delayed results, inadequate tissue sampling, fragmented workflows, and disparities in access. Beyond clinically actionable driver mutations, emerging research highlights radiogenomics and advances in the use of circulating tumor DNA for minimal residual disease detection, with important implications for early recurrence detection and patient prognostication, although these technologies differ in clinical maturity. Collectively, these developments emphasize the molecular heterogeneity underlying early-stage NSCLC and the expanding role of biomarkers in guiding clinical decision-making. Integrating genomic, radiographic, and biologic markers into clinical workflows will be essential to refine risk stratification, personalize perioperative treatment strategies, and ultimately improve long-term oncologic outcomes.
Related
- Editorial: Advancing non-small cell lung cancer management through biomarker integration
- Multi-omics integration identifies PON2 as a prognostic biomarker and mediator of tumor microenvironment remodeling in gallbladder cancer
- Tumor growth rate as a new imaging biomarker in early detection of lung cancer
- A clinicopathological and hematological biomarker-based nomogram for overall survival in early-onset colorectal cancer: development, external validation, and translational implications
- Response pathways and clinical workflow integration of digital symptom management platforms for breast cancer: A scoping review
BibTeX
@article{rabinovich2026biomarker,
title = {{Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer}},
author = {Emily P. Rabinovich and Linda W. Martin},
journal = {Journal of clinical medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15197644},
url = {https://europepmc.org/article/PMC/PMC13666488},
note = {CC BY},
}
RIS
TY - JOUR
TI - Biomarker Integration in the Perioperative Management of Early-Stage Non-Small-Cell Lung Cancer
AU - Emily P. Rabinovich
AU - Linda W. Martin
PY - 2026
DA - 2026/10/01
JO - Journal of clinical medicine
DO - 10.3390/jcm15197644
UR - https://europepmc.org/article/PMC/PMC13666488
AB - The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety and significant efficacy of biomarker-directed therapies in metastatic disease have fueled interest in applying precision oncology to early-stage, operable NSCLC. Advances in molecular profiling have revealed that a substantial proportion of resected NSCLC harbor actionable driver mutations, enabling the integration of targeted therapies into the perioperative setting. The success of adjuvant epidermal growth factor receptor and anaplastic lymphoma kinase inhibition established a framework for biomarker-driven therapy and highlights the importance of comprehensive molecular testing at diagnosis. In parallel, perioperative immune checkpoint inhibitor-based strategies have expanded treatment options for appropriately selected patients, further emphasizing the importance of molecular profiling. Significant implementation gaps remain, including incomplete molecular testing, delayed results, inadequate tissue sampling, fragmented workflows, and disparities in access. Beyond clinically actionable driver mutations, emerging research highlights radiogenomics and advances in the use of circulating tumor DNA for minimal residual disease detection, with important implications for early recurrence detection and patient prognostication, although these technologies differ in clinical maturity. Collectively, these developments emphasize the molecular heterogeneity underlying early-stage NSCLC and the expanding role of biomarkers in guiding clinical decision-making. Integrating genomic, radiographic, and biologic markers into clinical workflows will be essential to refine risk stratification, personalize perioperative treatment strategies, and ultimately improve long-term oncologic outcomes.
SN - 2077-0383
ER -